Cargando…

Dual targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: A novel structure-based design approach to treat COVID-19

With the rapid growth of the COVID-19 (coronavirus disease 2019) pandemic across the globe, therapeutic attention must be directed to fight the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, developing new antiviral drugs and vaccines is time-consuming, so one of the be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajpoot, Sajjan, Alagumuthu, Manikandan, Baig, Mirza S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726703/ https://www.ncbi.nlm.nih.gov/pubmed/33319212 http://dx.doi.org/10.1016/j.crstbi.2020.12.001

Ejemplares similares

Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein
por: Alagumuthu, Manikandan, et al.
Publicado: (2020)

Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells
por: Baig, Mirza S., et al.
Publicado: (2020)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 M(Pro) and PL(Pro)
por: Kattula, Bhavita, et al.
Publicado: (2023)

An overview of potential inhibitors targeting non-structural proteins 3 (PL(pro) and Mac1) and 5 (3CL(pro)/M(pro)) of SARS-CoV-2
por: Yan, Fangfang, et al.
Publicado: (2021)

Effects of diarylbutane lignans from Schisandra chinensis fruit on SARS-CoV-2 3CL(pro) and PL(pro) and their in vitro anti-inflammatory properties
por: Li, Bin, et al.
Publicado: (2023)

Spatial and temporal roles of SARS‐CoV PL(pro)—A snapshot
por: Yan, Shaomin, et al.
Publicado: (2020)

SARS-CoV-PL(pro)-Inhibitoren als mögliche Breitspektrum-Virostatika
por: Hammerschmidt, Stefan Josef, et al.
Publicado: (2021)

Schaftoside inhibits 3CL(pro) and PL(pro) of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
por: Yi, Yang, et al.
Publicado: (2022)

In Silico and In Vitro Inhibition of SARS-CoV-2 PL(pro) with Gramicidin D
por: Protić, Sara, et al.
Publicado: (2023)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CL(pro) and PL(pro)
por: Nagahawatta, D. P., et al.
Publicado: (2022)

“Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)"
por: Bhowmik, Deep, et al.
Publicado: (2021)

Computer-aided drug design for the pain-like protease (PL(pro)) inhibitors against SARS-CoV-2
por: Gao, Hongwei, et al.
Publicado: (2023)

FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M(pro) and PL(pro)
por: Tan, Haozhou, et al.
Publicado: (2023)

Profiling of Substrate Specificity of SARS-CoV 3CL(pro)
por: Chuck, Chi-Pang, et al.
Publicado: (2010)

Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2
por: Ohishi, Tomokazu, et al.
Publicado: (2022)

In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern
por: Rajpoot, Sajjan, et al.
Publicado: (2021)

Protocol for production and purification of SARS-CoV-2 3CL(pro)
por: Mazzei, Luca, et al.
Publicado: (2023)

Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (M(pro)) and Papain-like Protease (PL(pro))
por: Omage, Folorunsho Bright, et al.
Publicado: (2023)

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors
por: Regnier, Thomas, et al.
Publicado: (2009)

Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL(pro) covalent inhibitors
por: Stille, Julia K., et al.
Publicado: (2022)

A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor
por: Rajpoot, Sajjan, et al.
Publicado: (2021)

Pro- and Anti-Inflammatory Cytokine Expression Levels in Macrophages; An Approach to Develop Indazolpyridin-methanones as Novel Inflammation Medication
por: Alagumuthu, Manikandan, et al.
Publicado: (2020)

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)/3CL(pro) in Living Cells
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

In silico studies of M(pro) and PL(pro) from SARS-CoV-2 and a new class of cephalosporin drugs containing 1,2,4-thiadiazole
por: Delgado, Cássia Pereira, et al.
Publicado: (2022)

In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CL(pro)) and SARS-CoV-2 (M(pro))
por: Vergoten, Gérard, et al.
Publicado: (2021)

Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL(pro) and PL(pro)), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2)
por: Mouffouk, Chaima, et al.
Publicado: (2021)

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition
por: Ryu, Young Bae, et al.
Publicado: (2010)

Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022)

Machine learning prediction of 3CL(pro) SARS-CoV-2 docking scores
por: Bucinsky, Lukas, et al.
Publicado: (2022)

Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants
por: Jukič, Marko, et al.
Publicado: (2021)

MERS‐CoV papain-like protease (PL(pro)): expression, purification, and spectroscopic/thermodynamic characterization
por: Malik, Ajamaluddin, et al.
Publicado: (2017)

Fluorine Atoms on C(6)H(5)-Corrole Affect the Interaction with M(pro) and PL(pro) Proteases of SARS-CoV-2: Molecular Docking and 2D-QSAR Approaches
por: Chaves, Otávio Augusto, et al.
Publicado: (2022)

Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL(pro) inhibitors for treating COVID-19
por: Zhang, Jian-Wei, et al.
Publicado: (2022)

Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CL(pro) inhibitors against SARS-CoV-2
por: Yang, Hanxi, et al.
Publicado: (2023)

Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations
por: Solanki, Kundan, et al.
Publicado: (2022)

Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, M(pro) and PL(pro) of SARS-CoV-2: Protein–Protein Interactions, Dynamics Simulations and Free Energy Calculations
por: Naidoo, Devashan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_406acosn1emhr5algul3qii3ht